Sugi Predict

Sugi Predict / Compounds / SCHEMBL5322800

SCHEMBL5322800

SCHEMBL5322800

O=C(O)c1ccc(-c2ccn[nH]2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CD74 P04233 1/20 0.65
▸ MIF P14174 1/20 0.65
▸ SCN4A P35499 3/20 0.59
▸ BCAT2 O15382 1/20 0.58
▸ POLB P06746 1/20 0.55
▸ PTPN11 Q06124 1/20 0.55
▸ PDPK1 O15530 1/20 0.53
▸ NPC1 O15118 2/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ LTA4H P09960 1/20 0.51
▸ P2RY14 Q15391 1/20 0.51
▸ CYP4F2 P78329 4/20 0.49
▸ CYP4A11 Q02928 4/20 0.49
▸ HCAR2 Q8TDS4 1/20 0.48
▸ SLC13A5 Q86YT5 1/20 0.48
▸ NOS3 P29474 1/20 0.47
▸ NOS1 P29475 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methoxymethane SCHEMBL5324053 0.93 CD74 (0.58) CD74MIFSCN4ABCAT2POLB
SCHEMBL20662099 0.83 NOS3 (0.54) CD74MIFSCN4ABCAT2POLB
SCHEMBL32662754 0.83 NOS3 (0.54) CD74MIFSCN4ABCAT2POLB
SCHEMBL17279817 0.81 POLB (0.77) SCN4APOLBPTPN11PDPK1NPC1
SCHEMBL5323697 0.79 SCN4A (0.57) CD74MIFSCN4ABCAT2POLB
SCHEMBL3026361 0.74 SCN4A (1.00) CD74MIFSCN4ABCAT2POLB
SCHEMBL23294683 0.74 SCN4A (0.46) CD74MIFSCN4ABCAT2POLB
SCHEMBL22133061 0.74 ALOX5AP (0.52) —
SCHEMBL27917552 0.74 POLB (0.61) SCN4APOLBPTPN11PDPK1NPC1
SCHEMBL14414911 0.72 TP53 (0.44) NPC1RAB9AKDM4EALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 — — US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 — — EP disclosed
CN-113164459-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-03 — — CN disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 — — US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 — — US disclosed
US-20220332713-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-20 — — US disclosed
CN-113164459-A Monoacylglycerol lipase modulators 詹森药业有限公司 2021-07-23 — — CN disclosed
US-20200102303-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 — — US disclosed
EP-2731932-B1 AMINOMETHYL QUINOLONE COMPOUNDS HOFFMANN LA ROCHE (CH) 2015-12-30 — — EP disclosed
EP-2731932-A1 AMINOMETHYL QUINOLONE COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2014-05-21 — — EP disclosed
WO-2013007676-A1 AMINOMETHYL QUINOLONE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2013-01-17 — — WO disclosed
US-7300934-B2 Benzamide nitriles ROCHE PALO ALTO LLC (US) 2007-11-27 — — US disclosed
US-20070259879-A1 Piperazine and piperidine biaryl derivatives TRIMERIS, INC. 2007-11-08 — — US disclosed
US-20070259879-A1 Piperazine and piperidine biaryl derivatives TRIMERIS, INC. 2007-11-08 — — US disclosed
US-20070259879-A1 Piperazine and piperidine biaryl derivatives TRIMERIS, INC. 2007-11-08 — — US disclosed
WO-2007103456-A2 PIPERAZINE AND PIPERIDINE BIARYL DERIVATIVES TRIMERIS, INC. (US) 2007-09-13 — — WO disclosed
WO-2007103456-A2 PIPERAZINE AND PIPERIDINE BIARYL DERIVATIVES TRIMERIS, INC. (US) 2007-09-13 — — WO disclosed
EP-1633701-A1 BENZAMIDE NITRILE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-03-15 — — EP disclosed
WO-2004106285-A1 BENZAMIDE NITRILE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-12-09 — — WO disclosed
US-20040248949-A1 Benzamide nitriles ROCHE PALO ALTO LLC 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332713-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP CD74 4582/4885MIF 3717/4885SCN4A 1564/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH CD74 3744/4885MIF 3403/4885SCN4A 770/4885
US-20200102303-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP CD74 4582/4885MIF 3717/4885SCN4A 1564/4885
US-20230145249-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP CD74 4582/4885MIF 3717/4885SCN4A 1564/4885
US-20040248949-A1 Benzamide nitriles CTSK, CTSS, CMA1 CD74 1315/4885MIF 2669/4885SCN4A 137/4885
US-20070259879-A1 Piperazine and piperidine biaryl derivatives CYP3A5, CYP3A43, CCR5 CD74 1553/4885MIF 2119/4885SCN4A 2257/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP CD74 4582/4885MIF 3717/4885SCN4A 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.